Champions Oncolog (CSBR) Stock Price, Quote & News

Company Profile

Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotec...

Industry: Biotechnology

Sector: Healthcare

Phone: 201 808 8400

Website: www.championsoncology.com

Address:

One University Plaza, Suite 307, Hackensack, United States

Ned__ryerson Aug. 14 at 4:25 PM

$CSBR somebody dumped a slug of this stock premarket today (20k shares). There has been a large seller in the stock since the earnings report. They might be finished or they might not . I guess time will tell. It doesn’t take much to move this stock. I sure wish management would execute.

1 · Reply

glorrel Aug. 12 at 3:39 PM

$CSBR there is something seriously wrong with this stock

0 · Reply

glorrel Jul. 29 at 1:12 PM

$CSBR

0 · Reply

EarningsInsider Jul. 28 at 5:02 AM

https://www.marketbeat.com/earnings/reports/2026-7-27-champions-oncology-inc-stock/ $CSBR Champions Oncology Earnings Transcript

0 · Reply

focafoca99 Jul. 27 at 9:12 PM

$CSBR issued its audited FY 2026 results via press release.

0 · Reply

Ned__ryerson Jul. 27 at 8:44 PM

$CSBR another inspiring CC, with little apparent execution. Not even one question. I guess you can go back to sleep.

1 · Reply

StocktwitsEarnings Jul. 27 at 8:39 PM

$CSBR Q4 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.05 up 61.54% YoY • Reported revenue of $13.84M up 11.98% YoY

0 · Reply

MikeyMcDermott Jul. 17 at 7:44 PM

$CSBR these guys doing the no huddle earnings release again next week?

1 · Reply

Ned__ryerson Jun. 12 at 1:36 PM

$CSBR what is the deal with this thing? It trades very little volume. It goes up on 100 shares.

1 · Reply

SuperGreenToday Jun. 2 at 12:58 AM

$CSBR Share Price: $5.80 Contract Selected: Nov 20, 2026 $5 Calls Buy Zone: $1.72 – $2.13 Target Zone: $2.89 – $3.54 Potential Upside: 59% ROI Time to Expiration: 171 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Champions Oncology reports Q4 adjusted EPS 1c vs. (8c) last year

Jul 27, 2026, 4:30 PM EDT - 23 days ago

Champions Oncology Earnings Call Transcript: Q4 2026

Jul 27, 2026, 4:30 PM EDT - 23 days ago

Champions Oncology Earnings release: Q4 2026

Jul 27, 2026, 4:30 PM EDT - 23 days ago

Champions Oncology Annual report: Q4 2026

Jul 27, 2026, 4:00 PM EDT - 23 days ago

Champions Oncology Reports Record Annual Revenue of $59 Million

Jul 20, 2026, 4:30 PM EDT - 4 weeks ago

Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 27, 2026

Apr 9, 2026, 1:40 PM EDT - 4 months ago

Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026

Mar 30, 2026, 10:55 AM EDT - 5 months ago

Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy

Mar 12, 2026, 4:30 PM EDT - 5 months ago

Champions Oncology Earnings Call Transcript: Q3 2026

Mar 12, 2026, 4:30 PM EDT - 5 months ago

Champions Oncology Quarterly report: Q3 2026

Mar 12, 2026, 4:30 PM EDT - 5 months ago

Champions Oncology Earnings release: Q3 2026

Mar 12, 2026, 4:01 PM EDT - 5 months ago

Champions Oncology Reports Revenue of $16.6 Million

Mar 5, 2026, 4:00 PM EST - 5 months ago

Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2026

Dec 15, 2025, 4:30 PM EST - 8 months ago

Champions Oncology Earnings Call Transcript: Q2 2026

Dec 15, 2025, 4:30 PM EST - 8 months ago

Champions Oncology Quarterly report: Q2 2026

Dec 15, 2025, 4:30 PM EST - 8 months ago

Champions Oncology Earnings release: Q2 2026

Dec 15, 2025, 4:00 PM EST - 8 months ago

Champions Oncology Reports Record Quarterly Service Revenue of $14.9 Million

Dec 8, 2025, 4:00 PM EST - 9 months ago

Champions Oncology to Announce Second Quarter Financial Results on Monday, December 15, 2025

Sep 15, 2025, 4:50 PM EDT - 1 year ago

CORRECTION: Champions Oncology Reports Quarterly Revenue of $14.0 Million

Sep 15, 2025, 4:30 PM EDT - 1 year ago

Champions Oncology Earnings Call Transcript: Q1 2026

Sep 15, 2025, 4:30 PM EDT - 1 year ago

Champions Oncology Quarterly report: Q1 2026

Sep 15, 2025, 4:30 PM EDT - 1 year ago

Champions Oncology Earnings release: Q1 2026

Sep 15, 2025, 3:55 PM EDT - 1 year ago

Champions Oncology Reports Record Quarterly Revenue of $14.0 Million

Sep 10, 2025, 4:30 PM EDT - 1 year ago

Champions Oncology to Announce First Quarter Financial Results on Monday, September 15, 2025

Aug 22, 2025, 8:00 AM EDT - 1 year ago

Champions Oncology Proxy statement: Proxy Filing

Aug 22, 2025, 8:00 AM EDT - 1 year ago

Champions Oncology Proxy statement: Proxy Filing

2025-07-24T13:42:03.000Z - 1 year ago

Champions Oncology trading resumes

2025-07-24T13:35:57.000Z - 1 year ago

Champions Oncology trading halted, volatility trading pause

Jul 23, 2025, 4:30 PM EDT - 1 year ago

Champions Oncology Earnings Call Transcript: Q4 2025

Jul 23, 2025, 4:30 PM EDT - 1 year ago

Champions Oncology Annual report: Q4 2025

Jul 23, 2025, 4:30 PM EDT - 1 year ago

Champions Oncology Earnings release: Q4 2025

Jul 23, 2025, 4:00 PM EDT - 1 year ago

Champions Oncology Reports Record Annual Revenue of $57 Million

Jul 21, 2025, 8:30 AM EDT - 1 year ago

Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Wednesday, July 23, 2025

2025-07-18T12:35:46.000Z - 1 year ago

Champions Oncology appoints Rob Brainin as CEO

Jul 18, 2025, 8:30 AM EDT - 1 year ago

Champions Oncology Announces Appointment of New CEO

2025-07-08T12:56:03.000Z - 1 year ago

Champions Oncology announces launch of radiopharmaceutical services platform

Jul 8, 2025, 8:30 AM EDT - 1 year ago

Champions Oncology Launches Radiopharmaceutical Services Platform, Expands Isotope License, and Screens More Than 30 PDX Models

2025-04-28T13:51:31.000Z - 1 year ago

Champions Oncology obtains radioactive materials license

Apr 28, 2025, 9:45 AM EDT - 1 year ago

Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House

2025-04-24T12:56:14.000Z - 1 year ago

Champions Oncology collaborates with Turbine for data platform

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Champions Oncology's Data Platform Gains Momentum through a Strategic Collaboration with Turbine

2025-03-12T12:41:35.000Z - 1 year ago

Champions Oncology price target raised to $12 from $8 at Craig-Hallum

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Champions Oncology Earnings Call Transcript: Q3 2025

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Champions Oncology Quarterly report: Q3 2025

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Champions Oncology Earnings release: Q3 2025

Mar 11, 2025, 3:55 PM EDT - 1 year ago

Champions Oncology Reports Record Quarterly Revenue of $17.0 Million Record Net Income of $4.5 Million

Mar 6, 2025, 4:00 PM EST - 1 year ago

Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 11, 2025

Feb 18, 2025, 9:00 AM EST - 1 year ago

Champions Oncology Announces 17 Abstracts Accepted for Presentation at the 2025 American Association for Cancer Research Annual Meeting

2025-01-08T13:30:47.000Z - 1 year ago

Champions Oncology integrates Cytek Aurora flow cytometers

Jan 8, 2025, 8:00 AM EST - 1 year ago

Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership

2024-12-12T14:00:14.000Z - 1 year ago

Champions Oncology price target raised to $8 from $6 at Craig-Hallum

Dec 11, 2024, 4:30 PM EST - 1 year ago

Champions Oncology Earnings Call Transcript: Q2 2025

Dec 11, 2024, 4:30 PM EST - 1 year ago

Champions Oncology Quarterly report: Q2 2025

Dec 11, 2024, 4:30 PM EST - 1 year ago

Champions Oncology Earnings release: Q2 2025

Dec 11, 2024, 4:00 PM EST - 1 year ago

Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million

Dec 5, 2024, 4:30 PM EST - 1 year ago

Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024

2024-10-16T15:10:08.000Z - 2 years ago

Champions Oncology enters agreement with Weill Cornell Medicine

Oct 16, 2024, 10:55 AM EDT - 2 years ago

Champions Oncology Announces Agreement with Weill Cornell Medicine

2024-09-12T11:20:43.000Z - 2 years ago

Champions Oncology upgraded to Buy from Hold at Craig-Hallum

2024-09-11T21:35:24.000Z - 2 years ago

Champions Oncology reports Q1 EPS 11c vs. (16c) last year

2024-09-11T21:35:07.000Z - 2 years ago

Closing Bell Movers: Oxford Industries down 10% on earnings miss

NTGR OXM VNOM

Sep 11, 2024, 4:30 PM EDT - 2 years ago

Champions Oncology Earnings Call Transcript: Q1 2025

Sep 11, 2024, 4:30 PM EDT - 2 years ago

Champions Oncology Quarterly report: Q1 2025

Sep 11, 2024, 4:30 PM EDT - 2 years ago

Champions Oncology Earnings release: Q1 2025

Sep 11, 2024, 4:00 PM EDT - 2 years ago

Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million

Sep 9, 2024, 4:00 PM EDT - 2 years ago

Champions Oncology to Announce First Quarter Financial Results on Wednesday, September 11, 2024

Aug 27, 2024, 8:00 AM EDT - 2 years ago

Champions Oncology Proxy statement: Proxy Filing

Aug 27, 2024, 8:00 AM EDT - 2 years ago

Champions Oncology Proxy statement: Proxy Filing

2024-07-18T20:38:12.000Z - 2 years ago

Champions Oncology reports Q4 EPS 1c vs. (!7c) last year

Jul 18, 2024, 4:30 PM EDT - 2 years ago

Champions Oncology Earnings Call Transcript: Q4 2024

Jul 18, 2024, 4:30 PM EDT - 2 years ago

Champions Oncology Annual report: Q4 2024

Jul 18, 2024, 4:30 PM EDT - 2 years ago

Champions Oncology Earnings release: Q4 2024

Jul 18, 2024, 4:00 PM EDT - 2 years ago

Champions Oncology Reports Quarterly Revenue of $14.0 Million

Jul 11, 2024, 4:05 PM EDT - 2 years ago

Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Thursday, July 18, 2024

Jun 4, 2024, 9:00 AM EDT - 2 years ago

Champions Oncology and Medicines Discovery Catapult Forge Partnership to Accelerate Radiopharmaceutical Therapeutics Development

2024-03-13T12:42:07.000Z - 2 years ago

Craig-Hallum downgrades Champions Oncology to Hold amid challenging environment

2024-03-13T11:13:39.000Z - 2 years ago

Champions Oncology downgraded to Hold from Buy at Craig-Hallum

Mar 12, 2024, 4:30 PM EDT - 2 years ago

Champions Oncology Reports Quarterly Revenue of $12.0 Million

Mar 12, 2024, 4:30 PM EDT - 2 years ago

Champions Oncology Earnings Call Transcript: Q3 2024

Mar 12, 2024, 4:30 PM EDT - 2 years ago

Champions Oncology Quarterly report: Q3 2024

Mar 12, 2024, 4:30 PM EDT - 2 years ago

Champions Oncology Earnings release: Q3 2024

2024-03-07T14:09:30.000Z - 2 years ago

Champions Oncology’s U.S. laboratory receives CAP accreditation

Mar 7, 2024, 9:00 AM EST - 2 years ago

Champions Oncology's US Laboratory has Acquired Distinguished CAP Accreditation

Mar 6, 2024, 4:35 PM EST - 2 years ago

Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 12, 2024

Dec 12, 2023, 4:30 PM EST - 2 years ago

Champions Oncology Earnings Call Transcript: Q2 2024

Dec 12, 2023, 4:30 PM EST - 2 years ago

Champions Oncology Quarterly report: Q2 2024

Dec 12, 2023, 4:30 PM EST - 2 years ago

Champions Oncology Earnings release: Q2 2024

Dec 12, 2023, 4:00 PM EST - 2 years ago

Champions Oncology Reports Quarterly Revenue of $11.6 Million

Dec 4, 2023, 4:30 PM EST - 2 years ago

Champions Oncology to Announce Second Quarter Financial Results on Tuesday, December 12, 2023

Nov 2, 2023, 8:30 AM EDT - 3 years ago

Champions Oncology's European Research Operations Site Receives ISO-9001:2015 Accreditation and ATS Certification

Oct 17, 2023, 8:30 AM EDT - 3 years ago

Champions Oncology Announces the Addition of Brady Davis as President

Sep 13, 2023, 4:30 PM EDT - 3 years ago

Champions Oncology Earnings Call Transcript: Q1 2024

Sep 13, 2023, 4:30 PM EDT - 3 years ago

Champions Oncology Quarterly report: Q1 2024

Sep 13, 2023, 4:30 PM EDT - 3 years ago

Champions Oncology Earnings release: Q1 2024

Sep 13, 2023, 4:00 PM EDT - 3 years ago

Champions Oncology Reports Quarterly Revenue of $12.6 Million

Sep 11, 2023, 4:00 PM EDT - 3 years ago

Champions Oncology to Announce First Quarter Financial Results on Wednesday, September 13, 2023

Aug 28, 2023, 8:00 AM EDT - 3 years ago

Champions Oncology Proxy statement: Proxy Filing

Aug 28, 2023, 8:00 AM EDT - 3 years ago

Champions Oncology Proxy statement: Proxy Filing

Aug 22, 2023, 8:30 AM EDT - 3 years ago

Champions Oncology Aannounces Remarkable Lineup of Speakers at Its Translational Oncology Symposium in Boston in September 2023

Aug 1, 2023, 8:45 AM EDT - 3 years ago

Champions Oncology Announces a Multi-Year Agreement and Strategic Collaboration with BioVolume to Transform Reproducibility in Preclinical Oncology Efficacy Studies

Jul 24, 2023, 4:30 PM EDT - 3 years ago

Champions Oncology Earnings Call Transcript: Q4 2023

Jul 24, 2023, 4:30 PM EDT - 3 years ago

Champions Oncology Annual report: Q4 2023

Jul 24, 2023, 4:30 PM EDT - 3 years ago

Champions Oncology Earnings release: Q4 2023

Jul 24, 2023, 4:00 PM EDT - 3 years ago

Champions Oncology Reports Quarterly Revenue of $13.1 Million

Jul 20, 2023, 4:00 PM EDT - 3 years ago

Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 24, 2023

Apr 17, 2023, 8:30 AM EDT - 3 years ago

Champions Oncology Announces the Formation of Corellia AI, a Wholly Owned Biotech that Leverages Unique AI-Enabled Workflows for Novel Therapeutic Development

Apr 5, 2023, 9:50 AM EDT - 3 years ago

Champions Oncology Announces $5M Stock Repurchase Program

Mar 15, 2023, 4:30 PM EDT - 3 years ago

Champions Oncology Earnings Call Transcript: Q3 2023

Mar 15, 2023, 4:30 PM EDT - 3 years ago

Champions Oncology Quarterly report: Q3 2023

Mar 15, 2023, 4:30 PM EDT - 3 years ago

Champions Oncology Earnings release: Q3 2023

Mar 15, 2023, 3:50 PM EDT - 3 years ago

Champions Oncology Reports Quarterly Revenue of $12.8 Million

Mar 13, 2023, 8:30 AM EDT - 3 years ago

Champions Oncology to Announce Third Quarter Financial Results on Wednesday, March 15, 2023

Dec 13, 2022, 4:30 PM EST - 4 years ago

Champions Oncology Earnings Call Transcript: Q2 2023

Dec 13, 2022, 4:30 PM EST - 4 years ago

Champions Oncology Quarterly report: Q2 2023

Dec 13, 2022, 4:00 PM EST - 4 years ago

Champions Oncology Reports Record Quarterly Revenue of $14.3 Million

Dec 9, 2022, 4:30 PM EST - 4 years ago

Champions Oncology to Announce Second Quarter Financial Results on Tuesday, December 13, 2022

Sep 8, 2022, 4:30 PM EDT - 4 years ago

Champions Oncology Earnings Call Transcript: Q1 2023

Sep 8, 2022, 4:30 PM EDT - 4 years ago

Champions Oncology Quarterly report: Q1 2023

Sep 8, 2022, 4:00 PM EDT - 4 years ago

Champions Oncology Reports Record Quarterly Revenue of $13.7 Million

Sep 6, 2022, 4:00 PM EDT - 4 years ago

Champions Oncology to Announce First Quarter Financial Results on Thursday, September 8, 2022

Ned__ryerson Aug. 14 at 4:25 PM

1 · Reply

glorrel Aug. 12 at 3:39 PM

$CSBR there is something seriously wrong with this stock

0 · Reply

glorrel Jul. 29 at 1:12 PM

$CSBR

0 · Reply

EarningsInsider Jul. 28 at 5:02 AM

https://www.marketbeat.com/earnings/reports/2026-7-27-champions-oncology-inc-stock/ $CSBR Champions Oncology Earnings Transcript

0 · Reply

focafoca99 Jul. 27 at 9:12 PM

$CSBR issued its audited FY 2026 results via press release.

0 · Reply

Ned__ryerson Jul. 27 at 8:44 PM

$CSBR another inspiring CC, with little apparent execution. Not even one question. I guess you can go back to sleep.

1 · Reply

StocktwitsEarnings Jul. 27 at 8:39 PM

$CSBR Q4 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.05 up 61.54% YoY • Reported revenue of $13.84M up 11.98% YoY

0 · Reply

MikeyMcDermott Jul. 17 at 7:44 PM

$CSBR these guys doing the no huddle earnings release again next week?

1 · Reply

Ned__ryerson Jun. 12 at 1:36 PM

$CSBR what is the deal with this thing? It trades very little volume. It goes up on 100 shares.

1 · Reply

SuperGreenToday Jun. 2 at 12:58 AM

0 · Reply

MikeyMcDermott May. 6 at 6:30 PM

$CSBR what the heck is going on here? it is streaming 1-2 shares at a time at the ask ... like every second it keeps clicking. weird. Admittedly I haven't watched this trade for a while intraday because it is like watching paint dry. I was just doing a little research on Corellia and pulled up the ticker and noticed it.

1 · Reply

Ned__ryerson Apr. 27 at 6:20 PM

$CSBR jumpy again?? We Need a spark .

0 · Reply

topstockalerts Apr. 21 at 9:23 PM

After Hours Top Gainers PT2 $CSBR $MANH $TAC $TOUR $AXG

0 · Reply

Ned__ryerson Apr. 21 at 8:34 PM

$CSBR Stock is jumpy in AH. how come?

1 · Reply

focafoca99 Apr. 9 at 9:09 PM

$CSBR will present eight AACR posters focused on response and resistance modeling across several oncology settings.

0 · Reply

Ned__ryerson Apr. 9 at 6:14 PM

$CSBR https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/champions-oncology-to-present-new-data-on-predicting-response-and-res-1156457 These guys seem to be moving forward while their stock languishes.

0 · Reply

MikeyMcDermott Apr. 2 at 4:02 PM

$CSBR how is Lumin different than LTRN withzeta.ai ?

0 · Reply

MikeyMcDermott Mar. 31 at 3:56 PM

$CSBR this thing is going to have a huge run at some point ... the SaaS biz and the AI biotech drug discovery .... none of that is priced ... but this is probably the sleepiest name out there.

1 · Reply

PenkeInvesting Mar. 19 at 10:52 PM

Fundamental analysis of $CSBR (CHAMPIONS ONCOLOGY, INC.) based on financial data and reported results. #CSBR

1 · Reply

Bulltrader988 Mar. 12 at 11:03 PM

$CSBR 👃👀 https://x.com/i/status/2032207068644721051

0 · Reply

Bulltrader988 Mar. 12 at 11:03 PM

$CSBR 👃👀 https://finsee.ai/earnings/csbr/2026/q3/en

0 · Reply

Market Cap	70.72M
Revenue (ttm)	59.43M
Net Income (ttm)	-1.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1.99%
Debt to Equity Ratio	0.00

Volume	10,300
Avg Vol	9,180
Day's Range	N/A - N/A
Shares Out	13.89M
Stochastic %K	12%
Beta	0.40
Analysts	Strong Buy
Price Target	$12.00